Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls

Published on 12 Nov 2024 on Benzinga · via AOL

On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared...

Read the rest of the article

Start tracking your investments with Statfolio

Market Analysis by Charles-Henry Monchau covering: Silver Spot US Dollar, Silver Futures, BlackRo...

Investing.com 18 Nov 2024

As of the time of this writing, in premarket trading, MRNA shares are sitting around $39.18. Pfiz...

FastCompany · via Yahoo Finance 16 Nov 2024

U.S. stocks could open on a negative note on Friday after the Federal Reserve chair Jerome Powell...

Benzinga 15 Nov 2024

Kennedy Jr. to run the Department of Health and Human Services, potentially elevating a prominent...

Los Angeles Times 15 Nov 2024

Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to...

GuruFocus.com · via Yahoo Finance 13 Nov 2024

Novavax , Inc. (NASDAQ:NVAX), a biotechnology company specializing in vaccine development, report...

Investing.com 12 Nov 2024

On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compare...

Benzinga · via AOL 12 Nov 2024

On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compare...

Benzinga · via Yahoo Finance 12 Nov 2024

On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New...

Benzinga · via Yahoo Finance 11 Nov 2024

On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New...

Benzinga · via AOL 11 Nov 2024